Search research articles
Contact Us
Filters
Showing results (551-560 of 584) with videos related to
Page
of 59
Sort By:
Nature Cancer
|
August 7, 2023
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms
Elodie Grockowiak, Claudia Korn, Justyna Rak, et al.
Lancet (London, England)
|
January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Nature Medicine
|
March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Blood Advances
|
November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Aaron T Gerds, Michael R Savona, Bart L Scott, et al.
The New England Journal of Medicine
|
October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Jacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
The Lancet. Haematology
|
July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
American Journal of Hematology
|
November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
British Journal of Haematology
|
May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom
Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Nature Communications
|
November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Page
of 59
Search research articles
Search
Showing results (551-560 of 584) with videos related to
Sort By:
Page
of 59
Nature Cancer
|
August 7, 2023
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms
Elodie Grockowiak, Claudia Korn, Justyna Rak, et al.
Lancet (London, England)
|
January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Nature Medicine
|
March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Blood Advances
|
November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Aaron T Gerds, Michael R Savona, Bart L Scott, et al.
The New England Journal of Medicine
|
October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Jacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
The Lancet. Haematology
|
July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
American Journal of Hematology
|
November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
British Journal of Haematology
|
May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom
Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Nature Communications
|
November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Page
of 59